Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth

Area of Science:

• Immunology
• Oncology
• Infectious Diseases

Background:

• Infectious diseases and vaccines, such as BCG (Bacillus Calmette-Guérin), show protective associations with malignant melanoma risk.
• The innate immune system and microbial pattern recognition are crucial for immune tolerance to tumor antigens.
• Mycobacterium species, particularly Mycobacterium vaccae, possess strong adjuvant properties influencing immune responses.

Purpose of the Study:

• To investigate the association between infectious diseases and malignant melanoma risk.
• To explore the immunomodulatory potential of Mycobacterium vaccae in cancer immunity.
• To evaluate the need for clinical trials based on preliminary findings.

Main Methods:

• Review of studies on infectious diseases and melanoma risk by the European Organisation for Research and Treatment of Cancer (EORTC) working group FEBIM.
• Analysis of the role of microbial molecular patterns in activating antigen-presenting cells.
• Examination of evidence for Mycobacterium vaccae's effect on immune reactivity.

Main Results:

• Evidence suggests certain infectious diseases and vaccines (e.g., BCG) confer protection against malignant melanoma.
• Mycobacterium vaccae may down-regulate pro-tumor immune responses and promote anti-cancer immunity.
• Preliminary clinical observations and other cancer studies support further investigation.

Conclusions:

• Infectious diseases and specific microbial components like Mycobacterium vaccae hold potential in cancer immunotherapy.
• Further formal clinical trials are necessary to validate the anti-melanoma efficacy of Mycobacterium vaccae.